Equity Development Webinar for Investors

RNS Number : 4322Q

RUA Life Sciences PLC

19 June 2020

 

19 June 2020

RUA Life Sciences Plc

("RUA Life Sciences", the "Company" or the "Group")

Equity Development Webinar for Investors

RUA Life Sciences, the holding company of a group of medical device businesses focused on the exploitation of the world's leading long-term implantable biostable polymer (Elast-Eon^TM), is pleased to announce that Bill Brown, Chairman of the Company, will conduct a live presentation covering the recent changes within the business.

The event will take place at 11.00am on Thursday 25 June 2020.

The online presentation is open to both existing and potential shareholders. Questions can be submitted during the presentation and will be addressed at the end.

To register for the presentation, please visit:   https://zoom.us/webinar/register/7315924099563/WN_Hc0LVDn0SjGMVeywsNdEYQ

For further information contact:

RUA Life Sciences

Bill Brown, Chairman                                                    Tel: [phone]                                   

David Richmond, CEO  Tel: [phone]   

Shore Capital 

Tom Griffiths/David Coaten                                         Tel: [phone]

Equity Development                                                   Tel: [phone]

Hannah Crowe  [e-mail]    

About RUA Life Sciences

The RUA Life Sciences group was created in April 2020 when RUA Life Sciences Plc (formerly known as AorTech International Plc) acquired RUA Medical Devices Limited to create a fully formed medical device business. RUA Life Sciences is the holding company of the Group's four trading businesses, each exploiting the Group's patented polymer technology.

Our vision is to improve the lives of millions of patients by improving and enabling medical devices with Elast-Eon^TM, the world's leading long-term implantable polyurethane.

Whether it is licensing Elast-Eon^TM, manufacturing a device or component or developing next generation medical devices, a RUA Life Sciences business is pursuing our vision.

Elast-Eon™'s biostability is comparable to silicone while exhibiting excellent mechanical, blood contacting and flex-fatigue properties. These polymers can be processed using conventional thermoplastic extrusion and moulding techniques. With over 7 million implants and over 14 years of successful clinical use, RUA's polymers are proven in long-term life enabling applications.

The Group's four business units are:

RUA Medical :	End-to-end contract developer and manufacturer of medical devices and implantable fabric specialist.
RUA Biomaterials :	Licensor of Elast-EonTM polymers to the medical device industry.
RUA Vascular:	Development of large bore polymer sealed grafts and soft tissue patches.
RUA Structural Heart :	Development of tri leaflet polymeric heart valves.

 

END

 

 

NRAKZGMVVRVGGZM